Why Clovis Oncology Inc. Shares Took Off
Alex Planes, The Motley Fool - Motley Fool - 57 mins ago
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Clovis Oncology are trading 14% higher...
Incyte to Collaborate with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 57 mins ago
Incyte Corporation (INCY) inked a deal with MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 7 mins ago
Celldex Therapeutics, Inc. (CLDX) signed a deal with Bristol-Myers for the development of Celldex's varlilumab and Bristol-Myers' nivolumab in a phase I/II study.
After Yesterday's Rally of 2.90% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 2 hrs 33 mins ago
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $78.47 to a high of $80.62. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $79.18 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 2.90% Gain
Comtex SmarTrend(R) - 2 hrs 33 mins ago
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $78.47 to a high of $80.62. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $79.18 on volume of 6.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Exosomes Common Link in Cancer Drug Development
ACCESSWIRE - Thu May 15, 1:18PM CDT
Whitefish, MT / May 15, 2014 / The cancer drug business is ablaze lately as pharmaceutical companies of all sizes are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are being held in high regard as the next generation of cancer therapies as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465 for patients with advanced melanoma who did not respond to Bristol-Myers Squibb's (NYSE: BMY) Yervoy. Roche is making headlines not just with MK-3465, releasing data ahead of the May 30 start of this year's American Society of Clinical Oncology (ASCO) meeting, showing that its immune therapy drug MPDL3280A shrunk tumors in 10 of 20 bladder cancer patients. Pfizer (NYSE: PFE) is looking to consolidate some of its developmental pipeline through potentially the biggest biotech acquisition in history, offering more than $100 billion to buy AstraZeneca (NYSE: AZN). AstraZeneca's MedImmune unit is partnered with Pfizer, working on development of an anti-CTLA-4 combination therapy. MedImmune expanded its pipeline this week by inking a pact with Incyte (NASDAQ: INCY) to couple its MEDI4736 with Incyte's INCB24360 in a PD-L1-targeting regimen.
Global PCOS Drugs Market 2014-2018 with Bristol Myers Squibb, Merck & Co., Novartis AG, Sanofi SA & Teva Pharmaceutical Dominating
M2 - Thu May 15, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x7lhbh/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering. PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS. There has been a gradual increase in awareness of PCOS among the female population over the years. The acceptability of PCOS drugs is expected to rise because of the increasing public awareness of the syndrome and the need to treat it. This is expected to result in increasing drug penetration. In the recent past, there have been several awareness and educational programs specifically targeting patients with PCOS. For instance, September is celebrated annually as PCOS Awareness Month by the PCOS Foundation. The aim of the PCOS Foundation is to spread awareness through public and professional education programs to improve diagnosis and eliminate the lifetime risks associated with PCOS. The PCOS Foundation hosts a PCOS Awareness 5K Fun Run every September, which acts as part of the awareness campaign and encourages media discussion about PCOS. Thus, the increasing awareness and resultant higher treatment-seeking rates for PCOS are expected to contribute to the growth of the market. According to the report, the Global PCOS Drugs market is driven by several factors, of which an increase in the number of patients is one of the major drivers. Co-morbid conditions such as diabetes, obesity, and other cardiovascular complications lead to an increase in the number of PCOS patients. Further, the report states that lack of approved drugs for the treatment of PCOS is one of the main challenges. Since there are no specific approved products for the treatment of PCOS, the market is mainly dependent on treating conditions associated with PCOS by using various generic and off-label products. Key Vendors - Bristol Myers Squibb Co. - Merck & Co. Inc. - Novartis AG - Sanofi SA - Teva Pharmaceutical Inc. Other Prominent Vendors - AstraZeneca plc - Catalysis SL - Crinetics Pharmaceuticals Inc. - Dexa Medica Group - EffRx Inc. - Neurocrine Biosciences Inc. For more information visit http://www.researchandmarkets.com/research/x7...pcos_drugs
Today's Top Health Care Stocks to Watch: AstraZeneca plc, Clovis Oncology, Inc. and Incyte Corporati
George Budwell, The Motley Fool - Motley Fool - Thu May 15, 7:35AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AstraZeneca , Clovis Oncology , and Incyte Corporation . Will AstraZeneca and Clovis get an ASCO lift today? Shares of Clovis Oncology shot up close...
Ardelyx Receives $25 Million Milestone From AstraZeneca For Commencement Of Phase 2b Clinical Trial Of Tenapanor
PR Newswire - Thu May 15, 7:00AM CDT
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, in patients with end-stage renal disease on hemodialysis (ESRD-HD). With this payment, Ardelyx has received a total of $75 million in upfront and milestone payments from AstraZeneca under a worldwide exclusive license agreement announced in October 2012.
Why Pfizer's Huge Offer for AstraZeneca Actually Makes Sense
Bob Ciura, The Motley Fool - Motley Fool - Thu May 15, 6:00AM CDT
On the surface, offering $106 billion to take over a rival seems like nothing short of desperation. That's exactly what pharmaceutical giant Pfizer is doing, though, trying to acquire European competitor AstraZeneca . Pfizer has been through...
AstraZeneca sees deal hurdles
at Investor's Business Daily - Wed May 14, 5:40PM CDT
U.K. drugmaker AstraZeneca's (AZN) CEO, Pascal Soriot, on Wed. said he's open to talks with Pfizer (PFE) about a possible merger, but only if the price is right and certain risks are fully assessed, reports said. Soriot told Reuters he has concerns...
The First Look At Incyte's ASCO '14 Study Results
at The Street - Wed May 14, 4:00PM CDT
Incyte seeks to become a factor in the evolving race to develop new immuno-oncology drugs.
AstraZeneca Drug Shrinks Lung Cancers Typically Hardened by Genetic Mutation
at The Street - Wed May 14, 4:00PM CDT
The new and encouraging AZD9291 data come from a phase I study to be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting.
Bristol, Merck, AstraZeneca Bring New 'Checkpoint Inhibitor" Data to ASCO '14
at The Street - Wed May 14, 4:00PM CDT
New classes of drugs designed to dismantle cloaking mechanisms used by cancer cells to hide from a patient's immune system will dominate the buzz at this year's ASCO annual meeting.
Exosomes Part and Parcel of Celldex, Pfizer, Incyte and More Cancer Targets
ACCESSWIRE - Wed May 14, 2:50PM CDT
Whitefish, MT / May 14, 2014 / Pharmaceutical companies big and small are targeting a multitude of mechanisms of action to develop what they hope to be the next blockbuster cancer therapy. Immuno-oncology programs, namely PD-1 and PD-L1 inhibitors, are receiving the praise of analysts as Roche (OTCQX: RHHBY) races towards an FDA decision with MK-3465. Shares of Celldex Therapeutics (NASDAQ: CLDX) are chugging ahead by 25 percent on Wednesday after striking a deal with Bristol-Myers Squibb (NYSE: BMY) to collaborate on the clinical development of BMY's PD-1 investigational drug nivolumab in combination with Celldex's CD27-targeting drug candidate varlilumab.
Bristol, Celldex Collaborating on Cancer Immunotherapy Study
at The Street - Wed May 14, 9:39AM CDT
The phase I/II study will combine Bristol's PD-1 checkpoint inhibitor nivolumab with Celldex's CD27-targeted antibody varlilumab, also known as CDX-1127.
Rep. Delaney Hopes Pfizer Anger Will Fuel Infrastructure Bill (Correction)
at The Street - Wed May 14, 9:31AM CDT
Anger over tax-driven megadeals has been reignited by Pfizer's proposed acquisition of AstraZeneca and Rep. John Delaney is hoping to harness that outrage to help build momentum for his trademark infrastructure legislation.
Wednesday’s Top Health Care Stories: Isis Pharmaceuticals, Enzymotec, Incyte, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Wed May 14, 8:20AM CDT
Let's take a look at four stocks -- Isis Pharmaceuticals , Enzymotec , Incyte , and AstraZeneca -- that could make waves across the health-care sector this Wednesday morning. Isis surges on positive midstage results for diabetes...
Ligand Signs Research and Licensing Agreement with Omthera Pharmaceuticals for Dyslipidemia-related Diseases
Business Wire - Wed May 14, 7:31AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca plc (NYSE: AZN), for the development of products to treat dyslipidemia, including hypertriglyceridemia. The research collaboration will target the development of novel products that utilize the proprietary Ligand-developed LTP TECHNOLOGY(TM) to improve lipid-lowering activity of certain omega-3 fatty acids.
Global Diabetic Retinopathy Clinical Trials Report 2014
M2 - Wed May 14, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t9jfks/diabetic) has announced the addition of the "Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" report to their offering. Diabetic Retinopathy Global Clinical Trials Review, H1, 2014 provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Retinopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Retinopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Novartis AG - Pfizer Inc. - Valeant Pharmaceuticals International, Inc. - Allergan, Inc. - Takeda Pharmaceutical Company Limited - Eli Lilly and Company - AstraZeneca PLC - BCN Peptides, S.A. - National Eye Institute - University of Sao Paulo - National Taiwan University Hospital - Association for Innovation and Biomedical Research on Light and Image - Medical University of Vienna - Moorfields Eye Hospital NHS Foundation Trust - Diabetic Retinopathy Clinical Research Network - Shahid Beheshti University of Medical Sciences - HOSPITAL JUAREZ DE MEXICO - Federal University of Sao Paulo For more information visit http://www.researchandmarkets.com/research/t9jfks/diabetic